Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $6.52K in total
- 1
- 13F holdersQ2 2026, −2 vs. previous quarter
- 13
- 13F valueReported value at the end of Q2 2026
- $615.3K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CMMB, Q2 2026
No superinvestor reported holding CMMB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Chemomab Therapeutics Ltd. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 (view filing)10:05 AM ET | Aug 27-28 | 5 daysLate | Cohen Neil HarrisDirector | SSaleAmerican Depositary Shares | −2.30K | $2.83 | −$6.52K | −6.5%33.0K after | 2 lots |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Mor George AdiChief Executive Officer | PPurchaseAmerican Depositary Shares | −9.80K | $2.07 | −$20.2K | −6.6%139.1K after | 2 lots |
| Jan 5, 2023 (view filing)4:49 PM ET | Jan 3 | 2 days | OrbiMed Israel GP Ltd. and 1 other10% Owner | SSaleAmerican Depository Shares | −336.9K | $3.58 | −$1.21M | −13.1%2.24M after | 2 lots |
| Jan 5, 2023 (view filing) | Jan 3 | 2 days | Mor George AdiChief Scientific Officer | SSaleAmerican Depositary Shares | −7.70K | $5.03 | −$38.7K | −2.4%317.1K after | |
| Jan 5, 2023 (view filing) | Jan 3 | 2 days | Mor George AdiChief Scientific Officer | SSaleAmerican Depositary Shares | −6.10K | $5.03 | −$30.7K | −2.4%251.1K after | |
| Nov 18, 2022 (view filing) | Nov 16 | 2 days | Cohen Neil HarrisDirector | SSaleAmerican Depositary Shares | −2.41K | $2.00 | −$4.82K | −19.4%10.0K after | |
| Nov 17, 2022 (view filing) | Nov 16 | 1 day | Mor George AdiChief Scientific Officer | SSaleAmerican Depositary Shares | −324.8K | $2.08 | −$675.5K | −50.0%324.8K after | |
| Nov 17, 2022 (view filing) | Nov 16 | 1 day | Mor George AdiChief Scientific Officer | SSaleAmerican Depositary Shares | −257.2K | $2.08 | −$535.1K | −50.0%257.2K after | |
| Jun 21, 2022 (view filing) | Mar 16 | 97 daysLate | Marvin DonaldExecutive VP, CFO & COO | PPurchaseAmerican Depositary Shares | +500 | $3.28 | +$1.64K | +33.3%2.00K after | 2 lots |
| May 25, 2022 (view filing) | May 24 | 1 day | Maryles Joel MichaelDirector | PPurchaseAmerican Depositary Shares | +433 | $2.88 | +$1.25K | +43.3%1.43K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Chemomab Therapeutics Ltd. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 95,311 | $154.4K | 0.00% | +31,129+48.5% | Added |
| ADAR1 Capital Management, LLC | 80,000 | $129.6K | 0.01% | 00.0% | Unchanged |
| Kestra Private Wealth Services, LLC | 61,710 | $100.0K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 51,793 | $83.9K | 0.01% | 00.0% | Unchanged |
| Rhumbline Advisers | 30,529 | $49.5K | 0.00% | +12,163+66.2% | Added |
| XTX Topco Ltd | 15,987 | $25.9K | 0.00% | −2,642−14.2% | Reduced |
| Philadelphia Investment Partners, LLC | 15,000 | $24.3K | 0.02% | +6,800+82.9% | Added |
| Lido Advisors, LLC | 14,341 | $23.2K | 0.00% | +14,341 | New |
| BNP Paribas Arbitrage, SA | 6,805 | $11.0K | 0.00% | −1,620−19.2% | Reduced |
| GAMMA Investing LLC | 4,740 | $7.68K | 0.00% | −2,839−37.5% | Reduced |